Biodesix (NASDAQ:BDSX) Director Jack Schuler Purchases 142,045 Shares

Key Points

• Director Jack Schuler of Biodesix purchased 142,045 shares at an average price of $7.04, increasing his stake in the company by 11.47% to a total of 1,380,745 shares.
• Biodesix's stock price increased by 6.2%, reaching $7.60, although the company reported a weaker-than-expected EPS of ($1.60) in its recent quarterly earnings.
• Equities analysts have assigned Biodesix an average target price of $32.50 and rated the stock as a moderate buy, with one firm setting a target price of $20.00.

Biodesix, Inc. (NASDAQ:BDSX - Get Free Report) Director Jack Schuler acquired 142,045 shares of the firm's stock in a transaction that occurred on Friday, September 19th. The shares were purchased at an average cost of $7.04 per share, for a total transaction of $999,996.80. Following the completion of the acquisition, the director owned 1,380,745 shares in the company, valued at $9,720,444.80. This represents a 11.47% increase in their position. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Biodesix Trading Up 6.2%

Shares of BDSX stock traded up $0.45 during trading hours on Tuesday, reaching $7.60. The company's stock had a trading volume of 34,814 shares, compared to its average volume of 210,557. The company has a current ratio of 2.14, a quick ratio of 2.14 and a debt-to-equity ratio of 41.11. The firm's fifty day simple moving average is $8.01 and its 200 day simple moving average is $8.75. Biodesix, Inc. has a one year low of $3.44 and a one year high of $36.00. The stock has a market capitalization of $55.67 million, a P/E ratio of -1.32 and a beta of 1.00.

Biodesix (NASDAQ:BDSX - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The company reported ($1.60) EPS for the quarter, missing analysts' consensus estimates of ($1.40) by ($0.20). Biodesix had a negative net margin of 53.66% and a negative return on equity of 269.67%. The firm had revenue of $20.02 million for the quarter, compared to analysts' expectations of $18.47 million. Biodesix has set its FY 2025 guidance at EPS. Equities research analysts expect that Biodesix, Inc. will post -0.35 EPS for the current year.

Institutional Trading of Biodesix

A number of hedge funds have recently bought and sold shares of the stock. Monashee Investment Management LLC raised its stake in Biodesix by 15.7% in the first quarter. Monashee Investment Management LLC now owns 4,050,000 shares of the company's stock valued at $2,532,000 after buying an additional 549,121 shares during the period. Birchview Capital LP increased its position in Biodesix by 2.8% during the first quarter. Birchview Capital LP now owns 5,736,113 shares of the company's stock worth $3,586,000 after acquiring an additional 154,937 shares during the period. Northern Trust Corp grew its stake in Biodesix by 286.5% during the fourth quarter. Northern Trust Corp now owns 169,132 shares of the company's stock worth $259,000 after buying an additional 125,368 shares in the last quarter. XTX Topco Ltd acquired a new stake in Biodesix during the first quarter worth about $64,000. Finally, Jane Street Group LLC acquired a new stake in shares of Biodesix in the 4th quarter valued at approximately $119,000. 20.96% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the company. Canaccord Genuity Group set a $20.00 price objective on Biodesix and gave the stock a "buy" rating in a research note on Friday. Wall Street Zen upgraded shares of Biodesix to a "sell" rating in a research report on Saturday, September 13th. Four analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $32.50.

About Biodesix

Biodesix, Inc operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.